L. Ross

发表

Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens.

N. Graham, S. Raffanti, K. Henry, 2001, AIDS research and human retroviruses.

Impact of Switch to Fosamprenavir and Addition of Lovaza ® for Treatment of Hypertriglyceridemia in HIV-Infected Subjects on Antiretroviral Therapy

B. Ha, H. Khanlou, L. Ross, 2012 .

Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30–49 vs ≥50 mL/min

C. Gilks, A. Walker, D. Gibb, 2019, PloS one.

Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study.

R. Wallace,, K. Henry, L. Ross, 2001, The Journal of infectious diseases.

Safety and Efficacy of a 36-Week Induction Regimen of Abacavir/Lamivudine and Ritonavir-Boosted Atazanavir in HIV-Infected Patients

K. Squires, E. Dejesus, B. Young, 2010, HIV clinical trials.

Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravir

P. Jumes, J. Butterton, D. Panebianco, 2018, The Journal of antimicrobial chemotherapy.

Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results

B. Ha, E. Dejesus, C. Small, 2013, BMC Infectious Diseases.

Two Sensitive PCR-Based Methods for Detection of Hepatitis B Virus Variants Associated with Reduced Susceptibility to Lamivudine

F. Baldanti, K. Carrick, M. Lutz, 1999, Journal of Clinical Microbiology.

Rapid detection of the HIV type 1 reverse transcriptase codon T215Y by reverse transcription-polymerase chain reaction with fluorogenic probes.

A. Zimmermann, L. Ross, M. S. St. Clair, 1999, AIDS research and human retroviruses.

Substitution of a commercially available, RNA extraction procedure in an HIV-1 genotyping system improves sensitivity and allows reduced sample volume.

D. Mcclernon, L. Ross, M. S. St. Clair, 2001, Journal of virological methods.

HIV-1 Transmission Patterns in Antiretroviral Therapy-Naïve, HIV-Infected North Americans Based on Phylogenetic Analysis by Population Level and Ultra-Deep DNA Sequencing

James R. Brown, A. LaMarca, Samiul Hasan, 2014, PloS one.

Efficacy and Safety of Abacavir/Lamivudine/Zidovudine Plus Tenofovir in HBV/HIV-1 Coinfected Adults: 48-Week Data

B. Ha, D. Irlbeck, E. Dejesus, 2010, The open AIDS journal.

K. Squires, E. Dejesus, N. Bellos, 2010, AIDS.

Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine

C. Hoppel, G. McComsey, C. Cherry, 2005, AIDS.

Lack of Antagonism Between Abacavir, Lamivudine, and Tenofovir Against Wild-Type and Drug-Resistant HIV-1

R. Hazen, L. Ross, E. R. Lanier, 2005, Journal of acquired immune deficiency syndromes.

Sensitivity of phenotypic susceptibility analyses for nonthymidine nucleoside analogues conferred by K65R or M184V in mixtures with wild-type HIV-1.

N. Parkin, D. Irlbeck, L. Trinh, 2009, The Journal of infectious diseases.

Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263).

R. Redfield, B. Ha, C. Cohen, 2009, AIDS research and human retroviruses.

Pharmacokinetics, Safety and Antiviral Activity of Fosamprenavir/Ritonavir-containing Regimens in HIV-infected Children Aged 4 Weeks to 2 Years—48-week Study Data

M. Cotton, H. Cassim, N. Pavía-Ruz, 2013, The Pediatric infectious disease journal.

Estimated glomerular filtration rates through 144 weeks on therapy in HIV-1-infected subjects receiving atazanavir/ritonavir and abacavir/lamivudine or simplified to unboosted atazanavir/abacavir/lamivudine

A. LaMarca, K. Tashima, K. Squires, 2015, HIV clinical trials.

Effect of tenofovir subtraction on HIV plasma viraemia, CD4+ T-cell count and resistance in a patient with baseline K65R and M184V mutations

R. Hsu, L. Ross, K. Pappa, 2008, Antiviral therapy.

Once-Daily Abacavir/Lamivudine/Zidovudine plus Tenofovir for the Treatment of HIV-1 Infection in Antiretroviral-NaïveSubjects: A 48-Week Pilot Study

R. Redfield, B. Ha, C. Cohen, 2006, HIV clinical trials.

Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758.

D. Wohl, C. Hicks, E. Dejesus, 2009, AIDS research and human retroviruses.

Increased Adipocyte Apoptosis in Lipoatrophy Improves Within 48 Weeks of Switching Patient Therapy From Stavudine to Abacavir or Zidovudine

S. Wesselingh, G. McComsey, C. Cherry, 2005, Journal of acquired immune deficiency syndromes.

Differential Impact of Thymidine Analogue Mutations on Emtricitabine and Lamivudine Susceptibility

C. Chappey, N. Parkin, L. Ross, 2006, Journal of acquired immune deficiency syndromes.

Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance

C. Chappey, N. Parkin, M. Bates, 2004, AIDS.

Tenofovir (TDF)-selected or abacavir (ABC)-selected low-frequency HIV type 1 subpopulations during failure with persistent viremia as detected by ultradeep pyrosequencing.

R. D’Aquila, R. D'Aquila, S. Raffanti, 2011, AIDS research and human retroviruses.

Molecular basis of antagonism between K70E and K65R tenofovir-associated mutations in HIV-1 reverse transcriptase.

R. Kagan, M. Lewinski, R. Lloyd,, 2007, Antiviral research.

infection: 48-week results of ALERT

M. Fischl, Kimberly Smith, E. Dejesus, 2008 .

No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjects

B. Wynne, N. Arya, T. Eley, 2016, BMC Infectious Diseases.

ARIES 144 Week Results: Durable Virologic Suppression in HIV-Infected Patients Simplified to Unboosted Atazanavir/Abacavir/Lamivudine

D. Ward, K. Squires, E. Dejesus, 2012, HIV clinical trials.

Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.

J. Gallant, D. Berger, Allan E. Rodriguez, 2005, The Journal of infectious diseases.

Pharmacokinetics and 48-week Safety and Antiviral Activity of Fosamprenavir-containing Regimens in HIV-infected 2- to 18-year-old Children

M. Cotton, C. Fortuny, Y. Lou, 2013, The Pediatric infectious disease journal.

Changes from 2000 to 2009 in the Prevalence of HIV-1 Containing Drug Resistance-Associated Mutations from Antiretroviral Therapy-Naive, HIV-1-Infected Patients in the United States

D. Shortino, L. Ross, M. Shaefer, 2018, AIDS research and human retroviruses.

Impact of HIV subtype on response and resistance in antiretroviral-naïve adults comparing treatment with once daily versus twice daily ritonavir boosted fosamprenavir in combination with Abacavir/Lamivudine

H. Stellbrink, A. Lazzarin, G. Carosi, 2011 .

Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients.

M. Fischl, Kimberly Smith, E. Dejesus, 2010, AIDS research and human retroviruses.

Prevalence of Antiretroviral Drug Resistance and Resistance-Associated Mutations in Antiretroviral Therapy-Naïve HIV-Infected Individuals from 40 United States Cities

Allan E. Rodriguez, L. Ross, M. Shaefer, 2007, HIV clinical trials.

A truncated recombinant intercellular adhesion molecule-1 inhibits adhesion of leukemic cell lines to upregulated endothelial cells

C. M. Davis, L. Ross, L. Molony, 1994, In Vitro Cellular & Developmental Biology - Animal.

Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES.

K. Squires, D. Margolis, G. E. Pakes, 2012, AIDS research and human retroviruses.

HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects

D. Margolis, C. Small, L. Ross, 2017, BMC Infectious Diseases.

Impact of HIV type 1 drug resistance mutations and phenotypic resistance profile on virologic response to salvage therapy.

J. Tolson, K. Hertogs, B. Larder, 2001, AIDS research and human retroviruses.

The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy.

N. Graham, L. Ross, M. S. St. Clair, 1999, Journal of human virology.

Stavudine-associated peripheral neuropathy in zidovudine-naïve patients: Effect of stavudine exposure and antiretroviral experience

P. Shalit, Jaime E. Hernandez, L. Ross, 2002, Advances in therapy.

Antiretroviral Activity and Safety of Abacavir in Combination with Selected HIV-1 Protease Inhibitors in Therapy-Naive HIV-1-Infected Adults

R. Haubrich, M. Lederman, J. Mellors, 2000, Antiviral therapy.

Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia.

G. Fusco, L. Ross, M. S. St. Clair, 2002, AIDS research and human retroviruses.

Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors

J. Englund, R. McKinney, C. Baker, 2004, The Pediatric infectious disease journal.

Deletions in the beta3-beta4 hairpin loop of HIV-1 reverse transcriptase are observed in HIV-1 isolated from subjects during long-term antiretroviral therapy.

L. Boone, S. Short, R. Lanier, 2000, Journal of human virology.

Comparison of HIV type 1 protease inhibitor susceptibility results in viral samples analyzed by phenotypic drug resistance assays and by six resistance algorithms: an analysis of a subpopulation of the CHORUS cohort.

R. Boulmé, G. Fusco, A. Florance, 2005, AIDS research and human retroviruses.

A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir

M. Rizk, J. Butterton, K. Yee, 2017, Clinical Pharmacokinetics.

Simplification to Abacavir/Lamivudine + Atazanavir Maintains Viral Suppression and Improves Bone and Renal Biomarkers in ASSURE, a Randomized, Open Label, Non-Inferiority Trial

D. Wohl, E. Dejesus, D. Margolis, 2014, PloS one.

Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks

K. Squires, S. Walmsley, G. E. Pakes, 2017, HIV/AIDS.

P. Maruff, K. Robertson, D. Wohl, 2018, Journal of NeuroVirology.

Study of Once-Daily Versus Twice-Daily Fosamprenavir plus Ritonavir Administered with Abacavir/Lamivudine Once Daily in Antiretroviral-Naïve HIV-1–Infected Adult Subjects

H. Stellbrink, S. Staszewski, A. Lazzarin, 2009, HIV clinical trials.

A direct comparison of drug susceptibility to HIV type 1 from antiretroviral experienced subjects as assessed by the antivirogram and PhenoSense assays and by seven resistance algorithms.

J. Schmit, R. Boulmé, A. Florance, 2005, AIDS research and human retroviruses.

Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir

B. Ha, C. Cohen, J. Horton, 2009, The Journal of antimicrobial chemotherapy.

Short communication: the number of HIV major NRTI mutations correlates directly with other antiretroviral-associated mutations and indirectly with replicative capacity and reduced drug susceptibility.

N. Parkin, R. Lanier, L. Ross, 2008, AIDS research and human retroviruses.

P. Maruff, K. Robertson, D. Wohl, 2018, Journal of NeuroVirology.

Detection by ELISA of laminin released by endothelial cells from a collagen coated layer of Matrigel

A. Laurenza, L. Ross, 1995 .

Viral genetic heterogeneity in HIV-1-infected individuals is associated with increasing use of HAART and higher viremia

N. Graham, L. Ross, R. Demasi, 2000, AIDS.

Hiv/aids -research and Palliative Care Dovepress Response by Gender of Hiv-1-infected Subjects Treated with Abacavir/lamivudine plus Atazanavir, with or without Ritonavir, for 144 Weeks on Behalf of the Aries Study Team

K. Squires, S. Walmsley, G. E. Pakes, 2022 .

Differentiation of genotypic resistance profiles for amprenavir and lopinavir, a valuable aid for choice of therapy in protease inhibitor-experienced HIV-1-infected subjects.

Wendy Snowden, Margaret Tisdale, R. Elston, 2003, The Journal of antimicrobial chemotherapy.

A rare HIV reverse transcriptase mutation, K65N, confers reduced susceptibility to tenofovir, lamivudine and didanosine.

L. Ross, R. Dretler, Michael L. Lim, 2006, AIDS.

Erratum to: A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir

M. Rizk, J. Butterton, K. Yee, 2017, Clinical Pharmacokinetics.